Which has higher earnings & valuation, AORT or LIVN?

Artivion has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.21 $9.77M $0.24 83.83 LivaNova $1.39B 2.82 -$242.47M $1.95 36.52

Is AORT or LIVN more profitable?

LivaNova has a net margin of 7.48% compared to Artivion's net margin of 2.55%. LivaNova's return on equity of 16.48% beat Artivion's return on equity. Company Net Margins Return on Equity Return on Assets Artivion 2.55% 7.15% 3.63% LivaNova 7.48% 16.48% 7.59%

Does the media prefer AORT or LIVN?

In the previous week, LivaNova had 2 more articles in the media than Artivion. MarketBeat recorded 3 mentions for LivaNova and 1 mentions for Artivion. LivaNova's average media sentiment score of 0.58 beat Artivion's score of 0.00 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AORT or IRTC?

In the previous week, iRhythm Technologies had 4 more articles in the media than Artivion. MarketBeat recorded 5 mentions for iRhythm Technologies and 1 mentions for Artivion. iRhythm Technologies' average media sentiment score of 0.79 beat Artivion's score of 0.00 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iRhythm Technologies 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, AORT or NVST?

Envista has higher revenue and earnings than Artivion. Envista is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.21 $9.77M $0.24 83.83 Envista $2.72B 1.37 $47M $0.41 55.88

Is AORT or NVST more profitable?

Artivion has a net margin of 2.55% compared to Envista's net margin of 2.41%. Artivion's return on equity of 7.15% beat Envista's return on equity. Company Net Margins Return on Equity Return on Assets Artivion 2.55% 7.15% 3.63% Envista 2.41% 7.11% 3.91%

Which has higher earnings and valuation, AORT or MMED?

Artivion has higher earnings, but lower revenue than MiniMed Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.21 $9.77M $0.24 83.83 MiniMed Group $2.99B 1.31 N/A N/A N/A

Does the media favor AORT or MMED?

In the previous week, MiniMed Group had 7 more articles in the media than Artivion. MarketBeat recorded 8 mentions for MiniMed Group and 1 mentions for Artivion. MiniMed Group's average media sentiment score of 0.31 beat Artivion's score of 0.00 indicating that MiniMed Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Artivion (AORT) Competitors

$20.10 -0.32 (-1.57%)

As of 12:09 PM Eastern

Compare

AORT vs. LIVN, IRTC, NVST, MMED, and SLNO

Should you buy Artivion stock or one of its competitors? MarketBeat compares Artivion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Artivion include LivaNova (LIVN), iRhythm Technologies (IRTC), Envista (NVST), MiniMed Group (MMED), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry.

How does Artivion compare to LivaNova?

Artivion (NYSE:AORT) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Artivion has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.21	$9.77M	$0.24	83.83
LivaNova	$1.39B	2.82	-$242.47M	$1.95	36.52

In the previous week, LivaNova had 2 more articles in the media than Artivion. MarketBeat recorded 3 mentions for LivaNova and 1 mentions for Artivion. LivaNova's average media sentiment score of 0.58 beat Artivion's score of 0.00 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a net margin of 7.48% compared to Artivion's net margin of 2.55%. LivaNova's return on equity of 16.48% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.55%	7.15%	3.63%
LivaNova	7.48%	16.48%	7.59%

Artivion currently has a consensus target price of $46.17, suggesting a potential upside of 129.46%. LivaNova has a consensus target price of $79.38, suggesting a potential upside of 11.45%. Given Artivion's stronger consensus rating and higher possible upside, equities research analysts clearly believe Artivion is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

86.4% of Artivion shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Artivion has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Summary

LivaNova beats Artivion on 9 of the 16 factors compared between the two stocks.

How does Artivion compare to iRhythm Technologies?

Artivion (NYSE:AORT) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

86.4% of Artivion shares are held by institutional investors. 6.3% of Artivion shares are held by insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Artivion has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Artivion has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.21	$9.77M	$0.24	83.83
iRhythm Technologies	$747.14M	4.51	-$44.55M	-$0.86	N/A

In the previous week, iRhythm Technologies had 4 more articles in the media than Artivion. MarketBeat recorded 5 mentions for iRhythm Technologies and 1 mentions for Artivion. iRhythm Technologies' average media sentiment score of 0.79 beat Artivion's score of 0.00 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRhythm Technologies	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Artivion has a net margin of 2.55% compared to iRhythm Technologies' net margin of -3.53%. Artivion's return on equity of 7.15% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.55%	7.15%	3.63%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

Artivion currently has a consensus target price of $46.17, indicating a potential upside of 129.46%. iRhythm Technologies has a consensus target price of $189.69, indicating a potential upside of 85.01%. Given Artivion's higher possible upside, research analysts plainly believe Artivion is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

Summary

Artivion beats iRhythm Technologies on 9 of the 17 factors compared between the two stocks.

How does Artivion compare to Envista?

Artivion (NYSE:AORT) and Envista (NYSE:NVST) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Artivion had 1 more articles in the media than Envista. MarketBeat recorded 1 mentions for Artivion and 0 mentions for Envista. Envista's average media sentiment score of 1.00 beat Artivion's score of 0.00 indicating that Envista is being referred to more favorably in the news media.

Company	Overall Sentiment
Artivion	Neutral
Envista	Positive

86.4% of Artivion shares are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 1.0% of Envista shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Artivion has a net margin of 2.55% compared to Envista's net margin of 2.41%. Artivion's return on equity of 7.15% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.55%	7.15%	3.63%
Envista	2.41%	7.11%	3.91%

Artivion presently has a consensus price target of $46.17, indicating a potential upside of 129.46%. Envista has a consensus price target of $28.83, indicating a potential upside of 25.85%. Given Artivion's stronger consensus rating and higher probable upside, analysts clearly believe Artivion is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Artivion has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Envista has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Envista has higher revenue and earnings than Artivion. Envista is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.21	$9.77M	$0.24	83.83
Envista	$2.72B	1.37	$47M	$0.41	55.88

Summary

Artivion beats Envista on 11 of the 16 factors compared between the two stocks.

How does Artivion compare to MiniMed Group?

Artivion (NYSE:AORT) and MiniMed Group (NASDAQ:MMED) are both medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Artivion currently has a consensus price target of $46.17, suggesting a potential upside of 129.46%. MiniMed Group has a consensus price target of $21.67, suggesting a potential upside of 55.65%. Given Artivion's stronger consensus rating and higher probable upside, equities research analysts clearly believe Artivion is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, MiniMed Group had 7 more articles in the media than Artivion. MarketBeat recorded 8 mentions for MiniMed Group and 1 mentions for Artivion. MiniMed Group's average media sentiment score of 0.31 beat Artivion's score of 0.00 indicating that MiniMed Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.4% of Artivion shares are owned by institutional investors. Comparatively, 19.7% of MiniMed Group shares are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 2.2% of MiniMed Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Artivion has higher earnings, but lower revenue than MiniMed Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.21	$9.77M	$0.24	83.83
MiniMed Group	$2.99B	1.31	N/A	N/A	N/A

Artivion has a net margin of 2.55% compared to MiniMed Group's net margin of 0.00%. Artivion's return on equity of 7.15% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.55%	7.15%	3.63%
MiniMed Group	N/A	N/A	N/A

Summary

Artivion beats MiniMed Group on 8 of the 13 factors compared between the two stocks.

How does Artivion compare to Soleno Therapeutics?

Soleno Therapeutics (NASDAQ:SLNO) and Artivion (NYSE:AORT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Soleno Therapeutics has higher earnings, but lower revenue than Artivion. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95
Artivion	$441.33M	2.21	$9.77M	$0.24	83.83

97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by insiders. Comparatively, 6.3% of Artivion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Soleno Therapeutics presently has a consensus price target of $76.67, indicating a potential upside of 44.63%. Artivion has a consensus price target of $46.17, indicating a potential upside of 129.46%. Given Artivion's stronger consensus rating and higher probable upside, analysts clearly believe Artivion is more favorable than Soleno Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Soleno Therapeutics has a beta of -2.22, meaning that its stock price is 322% less volatile than the broader market. Comparatively, Artivion has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

In the previous week, Soleno Therapeutics and Soleno Therapeutics both had 1 articles in the media. Soleno Therapeutics' average media sentiment score of 0.94 beat Artivion's score of 0.00 indicating that Soleno Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Soleno Therapeutics	Positive
Artivion	Neutral

Soleno Therapeutics has a net margin of 33.70% compared to Artivion's net margin of 2.55%. Soleno Therapeutics' return on equity of 22.85% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	33.70%	22.85%	18.25%
Artivion	2.55%	7.15%	3.63%

Summary

Soleno Therapeutics beats Artivion on 9 of the 15 factors compared between the two stocks.

Get Artivion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AORT vs. The Competition

Export

Metric	Artivion	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$976.63M	$6.99B	$6.25B	$23.15B
Dividend Yield	N/A	1.21%	2.69%	4.09%
P/E Ratio	83.84	44.84	21.07	31.23
Price / Sales	2.21	86.81	556.32	14.76
Price / Cash	19.10	24.40	42.31	24.78
Price / Book	2.13	7.25	9.78	4.70
Net Income	$9.77M	$159.22M	$3.56B	$1.07B
7 Day Performance	-11.61%	1.30%	-0.18%	-0.15%
1 Month Performance	-44.52%	5.45%	4.95%	0.75%
1 Year Performance	-29.37%	2.48%	28.44%	26.30%

Artivion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AORT Artivion	3.8321 of 5 stars	$20.10 -1.6%	$46.17 +129.7%	-28.9%	$975.65M	$441.33M	83.75	1,800	Analyst Forecast
LIVN LivaNova	2.9793 of 5 stars	$73.83 flat	$79.38 +7.5%	+68.9%	$4.06B	$1.39B	37.86	3,300
IRTC iRhythm Technologies	4.0368 of 5 stars	$116.56 flat	$191.85 +64.6%	-25.0%	$3.83B	$747.14M	N/A	2,400	Analyst Forecast
NVST Envista	3.4695 of 5 stars	$23.41 -0.1%	$28.83 +23.2%	+26.6%	$3.81B	$2.72B	57.09	12,000	Positive News
MMED MiniMed Group	3.738 of 5 stars	$11.87 flat	$21.67 +82.5%	N/A	$3.33B	$2.99B	N/A	8,000	News Coverage Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AORT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artivion (AORT) Competitors

AORT vs. LIVN, IRTC, NVST, MMED, and SLNO

How does Artivion compare to LivaNova?

Summary

How does Artivion compare to iRhythm Technologies?

Summary

How does Artivion compare to Envista?

Summary

How does Artivion compare to MiniMed Group?

Summary

How does Artivion compare to Soleno Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT vs. The Competition

Artivion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artivion (AORT) Competitors

AORT vs. LIVN, IRTC, NVST, MMED, and SLNO

How does Artivion compare to LivaNova?

Which has higher earnings & valuation, AORT or LIVN?

Does the media prefer AORT or LIVN?

Is AORT or LIVN more profitable?

Do analysts recommend AORT or LIVN?

Do insiders & institutionals hold more shares of AORT or LIVN?

Which has more risk and volatility, AORT or LIVN?

Summary

How does Artivion compare to iRhythm Technologies?

Do insiders and institutionals believe in AORT or IRTC?

Which has more risk & volatility, AORT or IRTC?

Which has higher valuation & earnings, AORT or IRTC?

Does the media refer more to AORT or IRTC?

Is AORT or IRTC more profitable?

Do analysts rate AORT or IRTC?

Summary

How does Artivion compare to Envista?

Does the media refer more to AORT or NVST?

Do insiders and institutionals have more ownership in AORT or NVST?

Is AORT or NVST more profitable?

Do analysts prefer AORT or NVST?

Which has more risk and volatility, AORT or NVST?

Which has stronger earnings & valuation, AORT or NVST?

Summary

How does Artivion compare to MiniMed Group?

Do analysts recommend AORT or MMED?

Does the media favor AORT or MMED?

Do insiders and institutionals hold more shares of AORT or MMED?

Which has higher earnings and valuation, AORT or MMED?

Is AORT or MMED more profitable?

Summary

How does Artivion compare to Soleno Therapeutics?

Which has better valuation and earnings, SLNO or AORT?

Do institutionals and insiders believe in SLNO or AORT?

Do analysts rate SLNO or AORT?

Which has more risk & volatility, SLNO or AORT?

Does the media prefer SLNO or AORT?

Is SLNO or AORT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT vs. The Competition

Artivion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools